◆ 𝗦𝗖𝗢𝗣𝗘 Guided CEOs across biotech startups, private companies, and publicly traded firms, navigating complex challenges and maximizing growth potential.◆ 𝗢𝗥𝗚𝗔𝗡𝗜𝗭𝗔𝗧𝗜𝗢𝗡𝗔𝗟 𝗜𝗠𝗣𝗔𝗖𝗧:➞ Strengthened business development process for a US based consulting company and secured new projects through improvement of messaging, improved targeting, development of focused solutions and innovative partnerships which has resulted in the recent award of a significant government contract to one of company’s partnerships.➞ Facilitated improvement in a critical founder relationship within a Japanese company undergoing a capital reorganization by ensuring respectful communication, clear messaging and alignment of objectives, enabling them to expedite clinical development and secure Series D funding.➞ Provided strategic guidance to the CEO of a listed medicinal raw materials company during restructuring, ensuring a smooth transition before winding up.➞ Delivered commercial consulting expertise to a US-based AI company, enhancing their regulatory documentation strategies, identified and introduced company to new prospects which has resulted in first contract with a Cell & Gene Therapy client.➞ Architected new strategy for a leading Indian life science conglomerate to identify and showcase the true potential of their portfolio assets which led to successful negotiation and finalization of two $50 million USD term sheets.

◆ 𝗦𝗖𝗢𝗣𝗘 Retained to lead the creation of Biopharma Excellence, a new division of PharmaLex, by merging ERA Consulting GmbH and Biopharma Excellence GmbH, consolidating teams to become the market leader in the biopharma consulting market◆ 𝗢𝗥𝗚𝗔𝗡𝗜𝗭𝗔𝗧𝗜𝗢𝗡𝗔𝗟 𝗜𝗠𝗣𝗔𝗖𝗧:➞ Architected Biopharma Excellence's strategic identity and value proposition as the premier scientific-focused service provider, launching a new website that exceeded expectations with 20 qualified leads within the first month.➞ Shaped new strategy for authoring proposals through development of new proposal layout, templates covering each service and combinations, hired proposal manager which delivered 289 proposals authored and submitted with a 79%-win rate in 2022. ➞ Developed targeted sales process to understand the specific strategic product development and regulatory challenges encountered by companies developing biopharmaceutical products to craft targeted consulting solutions that delivered €23.1 million in sales + 37% vs. target in 2022.

◆ 𝗦𝗖𝗢𝗣𝗘: Hired to upgrade company operations and improve organisational operations and performance in preparation for owner exit.◆ 𝗢𝗥𝗚𝗔𝗡𝗜𝗭𝗔𝗧𝗜𝗢𝗡𝗔𝗟 𝗜𝗠𝗣𝗔𝗖𝗧:➞ Steered the company through a crisis in the wake of the scientific founder's sudden passing and CEO's absence by aligning planned actions and objectives with senior team, clear transparent communication with key clients and employees and continued delivery of projects which resulted in retention of all clients and key team members.➞ Orchestrated a comprehensive turnaround strategy, pivoting into the high-growth, low-competition field of Cell and Gene Therapy (C>), by leveraging scientific expertise and existing strategic capabilities, resulting in a 48% increase in Profit Before Tax (PBT) over 5 years.➞ Catalyzed a cultural transformation through enhanced communication, targeted team development, and competitive contract restructuring, reducing staff turnover and boosting revenue per consultant by 70% over five years.➞ Engineered and executed all facets of the exit strategy, encompassing buyer identification, pitch material creation, sale price negotiation, due diligence management, and sale agreement finalization, ultimately securing an above-market multiple for the company owner.

◆ 𝗦𝗖𝗢𝗣𝗘: Retained to establish operations in Malaysia, develop pipeline of revenue opportunities and identify investors◆ 𝗢𝗥𝗚𝗔𝗡𝗜𝗭𝗔𝗧𝗜𝗢𝗡𝗔𝗟 𝗜𝗠𝗣𝗔𝗖𝗧:➞ Established Cell Therapies in Malaysia, built partnerships with Government stakeholders, clinicians and hospitals, communicated Cell Therapies vision and strategy, completed application for investment status which led to award of BioNexus status for Cell Therapies Malaysia➞ Pioneered comprehensive search and evaluation activities for Cell Therapies strategy, developing due diligence processes, identifying aligned technologies, and negotiating with C-Suite leaders. Established a robust pipeline of 25 projects across Asia, Europe, and US, from initial evaluation to term sheet negotiation➞ Cultivated a strategic partnership with a global Malaysian conglomerate, aligning leadership visions and navigating investment processes, resulting in a board-approved $AUD 17 million term sheet for Cell Therapies.

◆ 𝗦𝗖𝗢𝗣𝗘: Appointed to improve governance and commence and complete clinical trial.◆ 𝗢𝗥𝗚𝗔𝗡𝗜𝗭𝗔𝗧𝗜𝗢𝗡𝗔𝗟 𝗜𝗠𝗣𝗔𝗖𝗧:➞ Led critical governance reforms, including CEO and director replacement, resulting in substantially improved corporate governance practices and earning commendation from the Nestlé chair.➞ Architected and implemented a financial strategy that secured $NZD 10M in non-dilutive funding over a 4-year period, significantly strengthening the company's financial position and extending the cash runway beyond initial projections.➞ Provided strategic guidance to the CEO in the successful execution of a multi-country clinical trial for irritable bowel syndrome, resulting in crucial endorsements from medical professionals and key investors for expanded product claims analysis.

◆ 𝗦𝗖𝗢𝗣𝗘: Contracted for 12 months to support Senior Executive Director to develop business development processes and prepare three projects for external partnering discussions.◆ 𝗢𝗥𝗚𝗔𝗡𝗜𝗭𝗔𝗧𝗜𝗢𝗡𝗔𝗟 𝗜𝗠𝗣𝗔𝗖𝗧:➞ Architected a comprehensive business development process, encompassing partner identification, evaluation, standardized pitch documents, and deal assessment. Implemented and refined the process across three institute projects, ensuring optimal effectiveness and adaptability.➞ Championed three scientific projects in collaboration with project leaders, leveraging a newly developed business development process. Crafted compelling presentations for potential partners, successfully advancing one project to high-level scientific due diligence.

◆ 𝗦𝗖𝗢𝗣𝗘: Contracted for 6 months to develop launch plans for Axona® in Canada, Australia, Asia, South America and Middle East.◆ 𝗢𝗥𝗚𝗔𝗡𝗜𝗭𝗔𝗧𝗜𝗢𝗡𝗔𝗟 𝗜𝗠𝗣𝗔𝗖𝗧:➞ Cultivated strategic relationships with potential partners, patient groups, target physicians, and government agencies, establishing a robust network to support product launch in Tier 1 markets.➞ Engineered comprehensive financial models and launch plans for Tier 1 markets, synthesizing complex data into compelling Board presentations to drive decision-making and market entry strategies.

◆ 𝗦𝗖𝗢𝗣𝗘: Hired to establish commercial operation across all group companies and secure first contracts.◆ 𝗢𝗥𝗚𝗔𝗡𝗜𝗭𝗔𝗧𝗜𝗢𝗡𝗔𝗟 𝗜𝗠𝗣𝗔𝗖𝗧:➞ Architected a comprehensive commercial strategy for InnoBioVentures, encompassing biosimilar development and CMO services. Positioned the company as a leading biopharma CMO, leveraging Patent Free Zone opportunities.➞ Orchestrated diverse business development initiatives, securing contracts in cell line development, manufacturing, and licensing. Navigated negotiations with global pharma companies and small biotech’s, establishing strategic partnerships and securing first CMO contracts.

◆ 𝗢𝗥𝗚𝗔𝗡𝗜𝗭𝗔𝗧𝗜𝗢𝗡𝗔𝗟 𝗜𝗠𝗣𝗔𝗖𝗧:➞ Architected the business plan and strategy, securing a $USD 120M term sheet for a global vaccine development startup.